|
1
|
Wiltshire JJ, Drake TM, Uttley L and
Balasubramanian SP: Systematic review of trends in the incidence
rates of thyroid cancer. Thyroid. 26:1541–1552. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song H, Lin C, Yao E, Zhang K, Li X, Wu Q
and Chuang PT: Selective ablation of tumor suppressors in
Parafollicular C cells elicits medullary thyroid carcinoma. J Biol
Chem. 292:3888–3899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American Thyroid Association Management
Guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American Thyroid Association
Guidelines Task Force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zarebczan B and Chen H: Multi-targeted
approach in the treatment of thyroid cancer. Minerva Chir.
65:59–69. 2010.PubMed/NCBI
|
|
6
|
Burman KD: Is poorly differentiated
thyroid cancer poorly characterized? J Clin Endocrinol Metab.
99:1167–1169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Vathaire F, Haddy N, Allodji RS,
Hawkins M, Guibout C, El-Fayech C, Teinturier C, Oberlin O,
Pacquement H, Diop F, et al: Thyroid radiation dose and other risk
factors of thyroid carcinoma following childhood cancer. J Clin
Endocrinol Metab. 100:4282–4290. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vigneri R, Malandrino P, Giani F, Russo M
and Vigneri P: Heavy metals in the volcanic environment and thyroid
cancer. Mol Cell Endocrinol. 457:73–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zevallos JP, Hartman CM, Kramer JR,
Sturgis EM and Chiao EY: Increased thyroid cancer incidence
corresponds to increased use of thyroid ultrasound and fine-needle
aspiration: A study of the Veterans Affairs health care system.
Cancer. 121:741–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, ; Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,
Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised
American Thyroid Association management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid.
19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ren M, Wu MC, Shang CZ, Wang XY, Zhang JL,
Cheng H, Xu MT and Yan L: Predictive factors of thyroid cancer in
patients with Graves' disease. World J Surg. 38:80–87. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tassinari J and Sisti A: Exophthalmos
(Graves' orbitopathy) in an ancient sculpture. J Endocrinol Invest.
39:1085–1086. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Smallridge RC, Ain KB, Asa SL, Bible KC,
Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal
MS, et al: American Thyroid Association guidelines for management
of patients with anaplastic thyroid cancer. Thyroid. 22:1104–1139.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee YS, Lim H, Chang HS and Park CS:
Papillary thyroid microcarcinomas are different from latent
papillary thyroid carcinomas at autopsy. J Korean Med Sci.
29:676–679. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Donatini G, Castagnet M, Desurmont T,
Rudolph N, Othman D and Kraimps JL: Partial thyroidectomy for
papillary thyroid microcarcinoma: Is completion total thyroidectomy
indicated? World J Surg. 40:510–515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goldfarb M and Casillas J: Unmet
information and support needs in newly diagnosed thyroid cancer:
Comparison of adolescents/young adults (AYA) and older patients. J
Cancer Surviv. 8:394–401. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grant CS: Papillary thyroid cancer:
Strategies for optimal individualized surgical management. Clin
Ther. 36:1117–1126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu W, Zhong M and Ai Z: Systematic
evaluation of prophylactic neck dissection for the treatment of
papillary thyroid carcinoma. Jpn J Clin Oncol. 43:883–888. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wells SA Jr, Asa SL, Dralle H, Elisei R,
Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, et al:
Revised American Thyroid Association guidelines for the management
of medullary thyroid carcinoma. Thyroid. 25:567–610. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dadu R, Devine C, Hernandez M, Waguespack
SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, et
al: Role of salvage targeted therapy in differentiated thyroid
cancer patients who failed first-line sorafenib. J Clin Endocrinol
Metab. 99:2086–2094. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schlumberger M, Parmentier C, Delisle MJ,
Couette JE, Droz JP and Sarrazin D: Combination therapy for
anaplastic giant cell thyroid carcinoma. Cancer. 67:564–566. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tennvall J, Lundell G, Wahlberg P,
Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL and Wallin G:
Anaplastic thyroid carcinoma: Three protocols combining
doxorubicin, hyperfractionated radiotherapy and surgery. Br J
Cancer. 86:1848–1853. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tuttle RM, Haddad RI, Ball DW, Byrd D,
Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, et al:
Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw.
12:1671–1680. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wilson L, Huang W, Chen L, Ting J and Cao
V: Cost effectiveness of Lenvatinib, Sorafenib and placebo in
treatment of radioiodine-refractory differentiated thyroid cancer.
Thyroid. 27:1043–1052. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K and
Chapman PB: Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim KB, Cabanillas ME, Lazar AJ, Williams
MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ and Sherman SI: Clinical
responses to vemurafenib in patients with metastatic papillary
thyroid cancer harboring BRAF(V600E) mutation. Thyroid.
23:1277–1283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abe Y, Matsumoto S, Kito K and Ueda N:
Cloning and expression of a novel MAPKK-like protein kinase,
lymphokine-activated killer T-cell-originated protein kinase,
specifically expressed in the testis and activated lymphoid cells.
J Biol Chem. 275:21525–21531. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shih MC, Chen JY, Wu YC, Jan YH, Yang BM,
Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M and Lai JM: TOPK/PBK
promotes cell migration via modulation of the PI3K/PTEN/AKT pathway
and is associated with poor prognosis in lung cancer. Oncogene.
31:2389–2400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park JH, Nishidate T, Nakamura Y and
Katagiri T: Critical roles of T-LAK cell-originated protein kinase
in cytokinesis. Cancer Sci. 101:403–411. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xing M, Haugen BR and Schlumberger M:
Progress in molecular-based management of differentiated thyroid
cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Treglia G, Aktolun C, Chiti A, Frangos S,
Giovanella L, Hoffmann M, Iakovou I, Mihailovic J, Krause BJ,
Langsteger W, et al: The 2015 Revised American Thyroid Association
guidelines for the management of medullary thyroid carcinoma: The
‘evidence-based’ refusal to endorse them by EANM due to the ‘not
evidence-based’ marginalization of the role of Nuclear Medicine.
Eur J Nucl Med Mol Imaging. 43:1486–1490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Matsuo Y, Park JH, Miyamoto T, Yamamoto S,
Hisada S, Alachkar H and Nakamura Y: TOPK inhibitor induces
complete tumor regression in xenograft models of human cancer
through inhibition of cytokinesis. Sci Transl Med. 6:259ra1452014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lay JD, Hong CC, Huang JS, Yang YY, Pao
CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ and Chuang SE:
Sulfasalazine suppresses drug resistance and invasiveness of lung
adenocarcinoma cells expressing AXL. Cancer Res. 67:3878–3887.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Robe PA, Bentires-Alj M, Bonif M, Rogister
B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP,
et al: In vitro and in vivo activity of the nuclear factor-kappaB
inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res.
10:5595–5603. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yuan J, Gu K, He J and Sharma S:
Preferential up-regulation of osteopontin in primary central
nervous system lymphoma does not correlate with putative receptor
CD44v6 or CD44H expression. Hum Pathol. 44:606–611. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Montgomery RM, Queiroz LS and Rogerio F:
EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in
glioblastoma: Therapeutic and prognostic correlation. Arq
Neuropsiquiatr. 73:561–568. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wienken CJ, Baaske P, Rothbauer U, Braun D
and Duhr S: Protein-binding assays in biological liquids using
microscale thermophoresis. Nat Commun. 1:1002010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jung SK, Lee KW, Byun S, Kang NJ, Lim SH,
Heo YS, Bode AM, Bowden GT, Lee HJ and Dong Z: Myricetin suppresses
UVB-induced skin cancer by targeting Fyn. Cancer Res. 68:6021–6029.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Irwin JJ, Sterling T, Mysinger MM, Bolstad
ES and Coleman RG: ZINC: A free tool to discover chemistry for
biology. J Chem Inf Model. 52:1757–1768. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fiser A and Sali A: Modeller: Generation
and refinement of homology-based protein structure models. Method
Enzymol. 374:461–491. 2003. View Article : Google Scholar
|
|
41
|
Kirubakaran P, Karthikeyan M, Singh KhD,
Nagamani S and Premkumar K: In silico structural and functional
analysis of the human TOPK protein by structure modeling and
molecular dynamics studies. J Mol Model. 19:407–419. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Abagyan R, Totrov M and Kuznetsov D: ICM-A
new method for protein modeling and design: Applications to docking
and structure prediction from the distorted native conformation. J
Computational Chemistry. 15:488–506. 1994. View Article : Google Scholar
|
|
43
|
Liu Z, Hou P, Ji M, Guan H, Studeman K,
Jensen K, Vasko V, El-Naggar AK and Xing M: Highly prevalent
genetic alterations in receptor tyrosine kinases and
phosphatidylinositol 3-kinase/akt and mitogen-activated protein
kinase pathways in anaplastic and follicular thyroid cancers. J
Clin Endocrinol Metab. 93:3106–3116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kunavisarut T: Diagnostic biomarkers of
differentiated thyroid cancer. Endocrine. 44:616–622. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang CC, Friedman L, Kennedy GC, Wang H,
Kebebew E, Steward DL, Zeiger MA, Westra WH, Wang Y, Khanafshar E,
et al: A large multicenter correlation study of thyroid nodule
cytopathology and histopathology. Thyroid. 21:243–251. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yassa L, Cibas ES, Benson CB, Frates MC,
Doubilet PM, Gawande AA, Moore FD Jr, Kim BW, Nosé V, Marqusee E,
et al: Long-term assessment of a multidisciplinary approach to
thyroid nodule diagnostic evaluation. Cancer. 111:508–516. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ferraz C, Eszlinger M and Paschke R:
Current state and future perspective of molecular diagnosis of
fine-needle aspiration biopsy of thyroid nodules. J Clin Endocr
Metab. 96:2016–2026. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nikiforov YE, Steward DL, Robinson-Smith
TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K
and Nikiforova MN: Molecular testing for mutations in improving the
fine-needle aspiration diagnosis of thyroid nodules. J Clin
Endocrinol Metab. 94:2092–2098. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Eszlinger M and Paschke R: Molecular
fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor
specific mutations and gene expression patterns. Mol Cell
Endocrinol. 322:29–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rao SN, Zafereo M, Dadu R, Busaidy NL,
Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, et
al: Patterns of treatment failure in anaplastic thyroid carcinoma.
Thyroid. 27:672–681. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vasko VV, Gaudart J, Allasia C, Savchenko
V, Di Cristofaro J, Saji M, Ringel MD and De Micco C: Thyroid
follicular adenomas may display features of follicular carcinoma
and follicular variant of papillary carcinoma. Eur J Endocrinol.
151:779–786. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Simons-Evelyn M, Bailey-Dell K, Toretsky
JA, Ross DD, Fenton R, Kalvakolanu D and Rapoport AP: PBK/TOPK is a
novel mitotic kinase which is upregulated in Burkitt's lymphoma and
other highly proliferative malignant cells. Blood Cells Mol Dis.
27:825–829. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Park JH, Lin ML, Nishidate T, Nakamura Y
and Katagiri T: PDZ-binding kinase/T-LAK cell-originated protein
kinase, a putative cancer/testis antigen with an oncogenic activity
in breast cancer. Cancer Res. 66:9186–9195. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhu F, Zykova TA, Kang BS, Wang Z, Ebeling
MC, Abe Y, Ma WY, Bode AM and Dong Z: Bidirectional signals
transduced by TOPK-ERK interaction increase tumorigenesis of HCT116
colorectal cancer cells. Gastroenterology. 133:219–231. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Brown-Clay JD, Shenoy DN, Timofeeva O,
Kallakury BV, Nandi AK and Banerjee PP: PBK/TOPK enhances
aggressive phenotype in prostate cancer via
b-catenin-TCF/LEF-mediated matrix metalloproteinases production and
invasion. Oncotarget. 6:15594–15609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sun H, Zhang L, Shi C, Hu P, Yan W, Wang
Z, Duan Q, Lu F, Qin L, Lu T, et al: TOPK is highly expressed in
circulating tumor cells, enabling metastasis of prostate cancer.
Oncotarget. 6:12392–12404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kim DJ, Li Y, Reddy K, Lee MH, Kim MO, Cho
YY, Lee SY, Kim JE, Bode AM and Dong Z: Novel TOPK inhibitor
HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res.
72:3060–3068. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Novel molecule targets cytokinesis. Cancer
Discov. 5:OF82015. View Article : Google Scholar
|
|
59
|
Tobinick EL: The value of drug
repositioning in the current pharmaceutical market. Drug News
Perspect. 22:119–125. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu Y, Liu H, Cao H, Song B and Zhang W
and Zhang W: PBK/TOPK mediates promyelocyte proliferation via
Nrf2-regulated cell cycle progression and apoptosis. Oncol Rep.
34:3288–3296. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shinde SR, Gangula NR, Kavela S, Pandey V
and Maddika S: TOPK and PTEN participate in CHFR mediated mitotic
checkpoint. Cell Signal. 25:2511–2517. 2013. View Article : Google Scholar : PubMed/NCBI
|
